Trader notes, earnings previews, Confluences, weekly digests and roundups — long-form analysis grounded in ORTEX short interest, options flow and analyst data.
Trader Note — 15017 total
Zymeworks enters June with a growing gap between where analysts think it should trade and where it actually is — a widening that has become the defining tension of the past month. The stock closed at $24.11 on June 2,…
VBNK delivered its Q2 2026 results this morning with a beat on revenue and an inline EPS print — but the numbers arrived against a backdrop of a quietly building short position and a cost-to-borrow that more than…
Fortive Corporation enters its June 9 earnings call with short sellers steadily unwinding positions — but the analyst community remains cautious, and options traders are nowhere near as defensive as they were just…
Willis Towers Watson enters June with a striking split personality: short sellers have been aggressively rebuilding positions since April's earnings collapse, while the CEO and a divisional president stepped in with…
Axsome Therapeutics heads into its Q1 2026 earnings call on Friday, June 5 carrying two competing signals: a freshly settled SUNOSI patent dispute that removes a meaningful overhang, and a persistent pattern of insider…
XLRE heads into June with an unusual combination: short sellers rebuilding positions at pace while the borrowing cost to fund those trades actually falls. The most striking development this week is the scale of short…
Madison Square Garden Sports Corp. heads into June with a striking split: short sellers have meaningfully rebuilt positions over the past week, yet options traders are the most bullish they have been all year. The…
CytomX Therapeutics enters a pivotal week with a headline-grabbing Regeneron collaboration pulling in one direction and a 14% stock decline pulling hard in the other. CytomX announced an expansion of its strategic…
Aclaris Therapeutics reports Q1 results tomorrow morning with a setup that cuts several ways at once: a fresh analyst initiation, a put/call ratio at its highest level in a year, and short sellers holding a meaningful…
KURA reports on June 4 with short sellers at their most aggressive in months and the stock down 14% on the week — the question now is whether Komzifti's commercial numbers can shift that conviction. Short interest has…
Houlihan Lokey enters June with a straightforward but uncomfortable setup: a cluster of C-suite sales at the exact top of the recent range, a stock that has since dropped 8.9% over the past month to $139.43, and short…
KHC enters the first week of June with two converging pressures: a fresh analyst downgrade from Bernstein and short interest that has climbed to its highest level in the 30-day window tracked here. The most striking…
Spyre Therapeutics enters June with an unusual combination: a stock that has drifted 6% lower on the week while the Street is broadly bullish, insider selling has been persistent, and short positions have quietly…
OLLI has reported June 3 earnings, and the week's central tension is now clear: short sellers are holding firm at elevated levels while the stock trades at a steep discount to where analysts think it belongs. The short…
ABVX entered June with what should have been its finest hour. The Phase 3 ABTECT maintenance trial for obefazimod in ulcerative colitis met its primary endpoint. Instead, shares closed at €63.10 on June 2 — down 43.6%…
FirstService Corporation arrives at a compelling inflection point this week — a freshly expanded share buyback programme collides with the steepest short-interest build in months, even as the stock logs its best weekly…
Shopify heads into its June 16 earnings with a familiar tension: the stock bounced hard this week, and the CEO sold into it again. The insider story continues to be the clearest signal on this name. Tobias Lütke sold…
MDT closed its fiscal fourth quarter with analysts cutting targets on earnings day itself — a clear signal that the Q4 print failed to close the gap between Street expectations and what the company actually…
SHAK enters its June 10 earnings call with the Street in damage-control mode — targets coming down hard, short sellers quietly reducing exposure, and the CEO who bought shares at $62 now watching them slip to $57. The…
Keysight Technologies enters the first week of June having given back some of the post-earnings momentum, with the stock slipping 2.6% on the week to $346.57 — even after a sharp 5% single-day rebound on June 2 that…
